Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

TYSABRI 300 mg concentrate for solution for infusion

Active Ingredient:
natalizumab
Company:  
Biogen Idec Ltd See contact details
ATC code: 
L04AA23
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Patient Alert Card

This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.

{pdf_link}

Treatment Initiation Form

This form should be read carefully before starting treatment with TYSABRI.

{pdf_link}

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with TYSABRI.

{pdf_link}

Treatment Continuation Form

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

{pdf_link}

Physician Information and Management Guidelines for Patients with Multiple Sclerosis receiving TYSABRI Therapy

{healthcare_pro_orange} For Healthcare Professionals

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Biogen Idec Ltd
Company image
Address
5 Foundation Park, Roxborough Way, Maidenhead, Berkshire, SL6 3UD, UK
Medical Information Direct Line
0800 008 7401
Medical Information e-mail
[email protected]
Medical Information Fax
+44 (0)1628 501 010